Coronavirus Disease 2019 (COVID-19)
FDA is working with U.S. government partners, including CDC, and international partners to address the pandemic.
Topic Paragraphs
Featured Topics
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
Jan 30
Daiso Issues Allergy Alert on Undeclared Soy in Matsunga Mini Shiruko Sand Biscuits
Food & Beverages
Jan 27
Sovos Brands Intermediate, Inc. Issues Allergy Alert on Undeclared Egg in Rao’s Slow Simmered Soup, Labeled as Chicken & Gnocchi but Containing Vegetable Minestrone
Food & Beverages
Jan 27
Edgewell Personal Care Issues Voluntary Nationwide Recall of Banana Boat Hair & Scalp Sunscreen Due to the Presence of Benzene – UPDATED
Drugs
Paragraph Header
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
FDA Approved Many New Drugs in 2022 That Will Improve the Lives of Patients and Consumers
In 2022, CDER approved 37 new drugs never before approved or marketed in the U.S., known as “novel” drugs.
Office of Digital Transformation’s New Focus on Technology Leadership
LMAP lays out our plans to strengthen our technology leadership capabilities to drive change at the business, technology, data, and cybersecurity levels.
FDA’s Cybersecurity Modernization Action Plan
CMAP will leverage Artificial Intelligence and Machine Learning technologies to enhance cyber detection and response capabilities.
Recently Published Guidances
Jan 31
Surveying, Leveling, and Alignment Laser Products
Radiation-Emitting Products
Jan 30
Acromegaly: Developing Drugs for Treatment
Drugs
Jan 30
CVM GFI #272 Practices to Prevent Unsafe Contamination of Animal Feed from Drug Carryover
Animal & Veterinary